Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
Authors
Keywords
-
Journal
Viruses-Basel
Volume 12, Issue 7, Pages 705
Publisher
MDPI AG
Online
2020-06-30
DOI
10.3390/v12070705
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structure analysis of the receptor binding of 2019-nCoV
- (2020) Yun Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
- (2020) Barnaby Edward Young et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus–A Possible Reference for Coronavirus Disease‐19 Treatment Option
- (2020) Tian‐Tian Yao et al. JOURNAL OF MEDICAL VIROLOGY
- Potential interventions for novel coronavirus in China: A systematic review
- (2020) Lei Zhang et al. JOURNAL OF MEDICAL VIROLOGY
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
- (2020) Clark D Russell et al. LANCET
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- An interactive web-based dashboard to track COVID-19 in real time
- (2020) Ensheng Dong et al. LANCET INFECTIOUS DISEASES
- COVID-19 and the cardiovascular system
- (2020) Ying-Ying Zheng et al. Nature Reviews Cardiology
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Covid-19 — Navigating the Uncharted
- (2020) Anthony S. Fauci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
- (2020) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
- (2020) Emmie de Wit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
- (2020) Markus Hoffmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
- (2020) Bo Li et al. Clinical Research in Cardiology
- Repurposing chlorpromazine to treat COVID-19: The reCoVery study
- (2020) M. Plaze et al. ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
- IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS
- (2020) Giancarlo Ceccarelli et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Teicoplanin: an alternative drug for the treatment of COVID-19?
- (2020) Sophie Alexandra Baron et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
- (2020) Zahra Sahraei et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
- (2020) Zhen Zhu et al. JOURNAL OF INFECTION
- COVID‐19 pneumonia treated with Sarilumab: a clinical series of eight patients
- (2020) Maurizio Benucci et al. JOURNAL OF MEDICAL VIROLOGY
- Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2
- (2020) Roberto Gomeni et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
- (2020) Huan Li et al. LEUKEMIA
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
- (2020) David E. Gordon et al. NATURE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
- (2020) Muthiah Vaduganathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug treatment options for the 2019-new coronavirus (2019-nCoV)
- (2020) Hongzhou Lu BioScience Trends
- Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment
- (2020) Luigi Buonaguro et al. Infectious Agents and Cancer
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
- (2020) Yadi Zhou et al. Cell Discovery
- Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
- (2020) Erin K McCreary et al. Open Forum Infectious Diseases
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- Should cyclosporine be useful in renal transplant recipients affected by SARS‐CoV‐2?
- (2020) Beatriz Rodriguez‐Cubillo et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- Type 1 interferons as a potential treatment against COVID-19
- (2020) Erwan Sallard et al. ANTIVIRAL RESEARCH
- Use of convalescent plasma in hospitalized patients with COVID-19: case series
- (2020) Livia Hegerova et al. BLOOD
- COVID-19, SARS and MERS: are they closely related?
- (2020) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
- (2020) Ling Li et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
- (2020) J.M. Molina et al. MEDECINE ET MALADIES INFECTIEUSES
- Coronavirus breakthrough: dexamethasone is first drug shown to save lives
- (2020) Heidi Ledford NATURE
- Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
- (2020) E. Susan Amirian et al. One Health
- Bats and Coronaviruses
- (2019) Arinjay Banerjee et al. Viruses-Basel
- A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
- (2019) Hisham Momattin et al. Travel Medicine and Infectious Disease
- Corticosteroids as Adjunctive Therapy in the Treatment of Influenza
- (2019) Louise E. Lansbury et al. CRITICAL CARE MEDICINE
- Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
- (2018) H.S. Li et al. ANTIVIRAL RESEARCH
- Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
- (2018) Min-Han Lin et al. ANTIVIRAL RESEARCH
- Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs
- (2018) Stanford Schor et al. DNA AND CELL BIOLOGY
- MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells
- (2018) Yu Cong et al. PLoS One
- Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
- (2018) Maria L. Agostini et al. mBio
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay
- (2016) Mizuki Yamamoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
- (2016) Nan Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion
- (2016) Christopher M. Coleman et al. JOURNAL OF VIROLOGY
- Toremifene interacts with and destabilizes the Ebola virus glycoprotein
- (2016) Yuguang Zhao et al. NATURE
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
- (2016) Jean-François Rossignol Journal of Infection and Public Health
- A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
- (2015) Yan Li et al. CELL RESEARCH
- Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
- (2014) Adriaan H. de Wilde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
- (2014) Julie Dyall et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
- (2014) Ali S Omrani et al. LANCET INFECTIOUS DISEASES
- The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
- (2014) J. M. Lucas et al. Cancer Discovery
- Cyclosporine has a potential role in the treatment of SARS
- (2013) Clark D. Russell et al. JOURNAL OF INFECTION
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
- (2012) M. Kawase et al. JOURNAL OF VIROLOGY
- Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
- (2011) James R. Smith et al. ADVANCES IN THERAPY
- Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
- (2011) Yusuf Yazici et al. ANNALS OF THE RHEUMATIC DISEASES
- Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
- (2011) Dale L Barnard et al. Future Virology
- Cyclosporin A inhibits the replication of diverse coronaviruses
- (2011) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model
- (2011) Tohru Miyoshi-Akiyama et al. JOURNAL OF INFECTIOUS DISEASES
- The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors
- (2011) Susanne Pfefferle et al. PLoS Pathogens
- Proteases: Multifunctional Enzymes in Life and Disease
- (2008) Carlos López-Otín et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
- (2008) K. Ratia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started